LENSAR, Inc.

As of September 12, 2025, LENSAR, Inc. shows a mildly bullish trend with mixed technical indicators, outperforming the S&P 500 significantly over the past year with a return of 195.24% compared to 17.14%.

As of November 9, 2020, LENSAR, Inc. is considered "risky" due to negative valuation metrics and overvaluation compared to peers, despite a strong year-to-date return of 38.7%.

As of November 9, 2020, LENSAR, Inc. is considered "risky" and overvalued due to negative financial metrics, including a Price to Book Value of -18.68 and a P/E ratio of -15.81, despite a strong 1-year stock return of 176.92%.

As of June 11, 2025, LENSAR, Inc. exhibits a neutral technical stance with mixed signals, as weekly indicators are mildly bearish while monthly indicators show a bullish trend, indicating a lack of clear direction.

LENSAR, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $14 million and a net loss of $27 million as of March 2025. It has a market cap of $146.31 million and key metrics indicating significant debt and negative price-to-book value.

As of Jun 18, LENSAR, Inc. has a market capitalization of 146.31 million and reported net sales of 57.07 million with a net profit of -56.58 million over the latest four quarters.